Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Kangma Biotechnology

Request full access

Next-generation biotech company leveraging DNA-to-Protein (D2P) technology to enable industrial-scale protein production

ChinaFounded 2015Biotech & Life Sciences

About Kangma Biotechnology

Kangma (Shanghai) Biotechnology Co., Ltd., operating under the trade name OurProteinFactory.com, is a biotechnology firm established in 2015. The company is positioned to address the market for high-value protein synthesis and disease diagnostics. Its core operations are centered around a proprietary, patented D2P (DNA-to-Protein) technology.

The company's primary offering, the ProteinFactory system, is an engineered, eukaryote-based, cell-free protein synthesis platform. This system consolidates the entire central dogma of molecular biology—DNA duplication, RNA transcription, and protein translation—into a single in-vitro process. A key operational advantage is its ability to produce folded proteins at room temperature (20-30°C) in approximately three hours, a significant time reduction compared to traditional methods. The technology reportedly increases protein yield by 10 to 1,000 times compared to other cell-free kits while substantially lowering costs. Kangma Biotechnology serves a client base primarily composed of academic and research institutions, providing tools for teaching and research purposes.

Revenue is generated through the sale of its ProteinFactory kits and a suite of related services. The business model includes offering standardized kits (e.g., Array, NMR, High Yield) and a customization service where clients can provide a protein sequence to receive a bespoke kit for its synthesis. This is facilitated through its e-commerce platform on OurProteinFactory.com and a dedicated mobile app, 'Proteinn'. Beyond protein synthesis, the company is developing a broader platform incorporating big data analysis, cloud computing, and AI services related to genes and proteins, alongside developing disease diagnosis microchips.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
21.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Medical & Healthcare, Health Diagnostics, Synthetic Biology, DT and LS, science-based
Technology
Deep Tech
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES C✓Equity / VC Apr 2025 $28M $110M Undisclosed ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Kangma Biotechnology website traffic

Latest recorded traffic for Kangma Biotechnology is 460 monthly website visits, down 43.2% over the last three months.

Latest monthly visits460 3-month web change-43.2%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Kangma Biotechnology in its local ecosystem

Live from Dealroom

The Kangma Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Kangma Biotechnology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Kangma Biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.